A Preliminary Investigation of Individual Differences in Subjective Responses to D-Amphetamine, Alcohol, and Delta-9-Tetrahydrocannabinol Using a Within-Subjects Randomized Trial

Wardle, Margaret C.; Marcus, Benjamin; Wit, Harriet de

doi:10.1371/journal.pone.0140501

Cited by 54 publications

(13 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…One study demonstrated a greater increase in cannabis-induced “high” in female cannabis users compared to males [122], yet another study in non-users exposed to cannabis reported greater increases in “high” ratings in males compared to females [123]. Conflicting evidence may be due to smoking status differences in the populations of each study, as well as differences in THC capsule dosing indicated in each experimental design.…”

Section: Sex Differences In the Rewarding Properties Of Cannabinoidsmentioning

confidence: 99%

Mechanisms Underlying Sex Differences in Cannabis Use

et al. 2017

View full text Add to dashboard Cite

Purpose of the Review Cannabis is the most commonly used illicit substance worldwide. In recent decades, highly concentrated products have flooded the market, and prevalence rates have increased. Gender differences exist in cannabis use, as men have higher prevalence of both cannabis use and cannabis use disorder (CUD), while women progress more rapidly from first use to CUD. This paper reviews findings from preclinical and human studies examining the sex-specific neurobiological underpinnings of cannabis use and CUD, and associations with psychiatric symptoms. Recent Findings Sex differences exist in the endocannabinoid system, in cannabis exposure effects on brain structure and function, and in the co-occurrence of cannabis use with symptoms of anxiety, depression and schizophrenia. In female cannabis users, anxiety symptoms correlate with larger amygdala volume and social anxiety disorder symptoms correlate with CUD symptoms. Female cannabis users are reported to be especially vulnerable to earlier onset of schizophrenia, and mixed trends emerge in the correlation of depressive symptoms with cannabis exposure in females and males. Summary As prevalence of cannabis use may continue to increase given the shifting policy landscape regarding marijuana laws, understanding the neurobiological mechanisms of cannabis exposure in females and males is key. Examining these mechanisms may help inform future research on sex-specific pharmacological and behavioral interventions for women and men with high-risk cannabis use, comorbid psychiatric disease, and CUD.

show abstract

Section: Sex Differences In the Rewarding Properties Of Cannabinoidsmentioning

confidence: 99%

Mechanisms Underlying Sex Differences in Cannabis Use

et al. 2017

View full text Add to dashboard Cite

show abstract

“…At the same time, relatively higher amounts found in Bedrocan ® -MCT deserve further study as it was demonstrated that this heptyl Δ 9 -THC homologous showed a cannabimimetic activity several times higher than Δ 9 -THC, both under in vitro and in vivo conditions [ 8 ]. The discovery of this extremely potent Δ 9 -THC-like phytocannabinoid in both the Bedrocan ® and Bediol ® chemotype may explain several pharmacological effects not attributable exclusively to Δ 9 -THC [ 37 ]. The results of this study, although preliminary, indicate that in deep investigation toward the presence of untarget cannabonoid, such as Δ 9 -THCP, would be strategic, in order to characterize the different cannabis chemotypes involved in disease treatment.…”

Section: Resultsmentioning

confidence: 99%

Impact of Lipid Sources on Quality Traits of Medical Cannabis-Based Oil Preparations

Ramella¹,

Roda

Pavlović

et al. 2020

Molecules

View full text Add to dashboard Cite

The feasibility of the use of two lipid sources and their impact on the cannabinoid profile, terpene fingerprint, and degradation products in medical cannabis oil preparations during 3 months of refrigerated storage time were investigated. LCHRMS-Orbitrap® and HS-SPME coupled to GC-MS for the investigation of targeted and untargeted cannabinoids, terpenes, and lipid degradation products in Bedrocan® and Bediol® macerated oils were used as analytical approaches. As regards the cannabinoid trend during 90 days of storage, there were no differences between PhEur-grade olive oil (OOPH) and medium-chain triglycerides oil (MCT oil) coupled to a good stability of preparations for the first 60 days both in Bedrocan® and Bediol® oils. MCT lipid source extracted a significant concentration of terpenes compared to olive oil. Terpenes showed a different scenario since MCT oil displayed the strongest extraction capacity and conservation trend of all compounds during the shelf life. Terpenes remained stable throughout the entire storage period in MCT formulations while a significant decrease after 15 and 30 days in Bediol® and Bedrocan® was observed in olive oil. Therefore, MCT oil could be considered a more suitable lipid source compared to olive oil involved in the extraction of medical cannabis for magistral preparations.

show abstract

“…It has been demonstrated in animals and humans that THC has differential effects in males and females. 70 Sex differences have been observed in the pharmacokinetics, [71][72][73][74] pharmacodynamics, [75][76][77][78] subjective effects, [79][80][81][82] abuse liability, [83][84][85][86] and therapeutic potential of THC (for recent review see Cooper and Craft 70 ). Thus, other agents that target the endocannabinoid system, such as CBD, might be expected to have similar sex-dependent effects.…”

Section: Sex Differences In Anxiety and The Utility Of Cbdmentioning

confidence: 99%

Use of Cannabidiol for the Treatment of Anxiety: A Short Synthesis of Pre-Clinical and Clinical Evidence

Wright

Ciano

Brands

2020

Cannabis and Cannabinoid Research

View full text Add to dashboard Cite

Anxiety disorders have the highest lifetime prevalence of any mental illness worldwide, leading to high societal costs and economic burden. Current pharmacotherapies for anxiety disorders are associated with adverse effects and low efficacy. Cannabidiol (CBD) is a constituent of the Cannabis plant, which has potential therapeutic properties for various indications. After the recent legalization of cannabis, CBD has drawn increased attention as a potential treatment, as the majority of existing data suggest it is safe, well tolerated, has few adverse effects, and demonstrates no potential for abuse or dependence in humans. Pre-clinical research using animal models of innate fear and anxiety-like behaviors have found anxiolytic, antistress, anticompulsive, and panicolytic-like effects of CBD. Preliminary evidence from human trials using both healthy volunteers and individuals with social anxiety disorder, suggests that CBD may have anxiolytic effects. Although these findings are promising, future research is warranted to determine the efficacy of CBD in other anxiety disorders, establish appropriate doses, and determine its long-term efficacy. The majority of pre-clinical and clinical research has been conducted using males only. Among individuals with anxiety disorders, the prevalence rates, symptomology, and treatment response differ between males and females. Thus, future research should focus on this area due to the lack of research in females and the knowledge gap on sex and gender differences in the effectiveness of CBD as a potential treatment for anxiety.

show abstract

A Preliminary Investigation of Individual Differences in Subjective Responses to D-Amphetamine, Alcohol, and Delta-9-Tetrahydrocannabinol Using a Within-Subjects Randomized Trial

Cited by 54 publications

References 61 publications

Mechanisms Underlying Sex Differences in Cannabis Use

Mechanisms Underlying Sex Differences in Cannabis Use

Impact of Lipid Sources on Quality Traits of Medical Cannabis-Based Oil Preparations

Use of Cannabidiol for the Treatment of Anxiety: A Short Synthesis of Pre-Clinical and Clinical Evidence

Contact Info

Product

Resources

About